Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52–8.
Article
CAS
Google Scholar
Van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1330.
Article
Google Scholar
Goldman JD, Wang K, Roltgen K, et al. Reinfection with SARS-CoV-2 and failure of humoral immunity: a case report. MedRxiv. 2020. https://doi.org/10.1101/2020.09.22.20192443.
Article
PubMed
PubMed Central
Google Scholar
Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32.
Article
CAS
Google Scholar
Wang SF, Tseng SP, Yen CH, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208–14.
Article
CAS
Google Scholar
Du LY, Tai WB, Zhou YS, et al. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016;15(9):1123–34.
Article
CAS
Google Scholar
Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81.
Article
CAS
Google Scholar
Li D, Edwards RJ, Manne K, et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. BioRxiv. 2021. https://doi.org/10.1101/2020.12.31.424729.
Article
PubMed
PubMed Central
Google Scholar
Liu Y, Soh WT, Kishikawa J, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021. https://doi.org/10.1101/2020.12.18.423358v1.
Article
PubMed
PubMed Central
Google Scholar
Gan L, Chen Y, Hu PP, et al. Willingness to receive SARS-CoV-2 vaccination and associated factors among chinese adults: a cross sectional survey. Int J Environ Res Public Health. 2021. https://doi.org/10.3390/ijerph18041993.
Article
PubMed
PubMed Central
Google Scholar
Dos Santos LA, de Góis Filho PG, Silva AM, et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infect. 2021;82(3):399–406.
Article
Google Scholar
Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459–69.
Article
CAS
Google Scholar
Murillo-Zamora E, Mendoza-Cano O, Delgado-Enciso I, et al. Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. Public Health. 2021;193:113–5.
Article
CAS
Google Scholar
Bailly B, Guilpain L, Bouiller K, et al. BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab446.
Article
PubMed
Google Scholar
Singh C, Naik BN, Pandey S, et al. Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India. Epidemiol Infect. 2021;149:e224.
Article
CAS
Google Scholar
Slezak J, Bruxvoort K, Fischer H, et al. Rate and severity of suspected SARS-Cov2 reinfection in a cohort of PCR-positive COVID-19 patients. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.07.030.
Article
PubMed
PubMed Central
Google Scholar
Baden LR, ElSahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.
Article
CAS
Google Scholar
Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81.
Article
CAS
Google Scholar
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
Article
CAS
Google Scholar
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201.
Article
CAS
Google Scholar
Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2102214.
Article
PubMed
PubMed Central
Google Scholar
Benham JL, Atabati O, Oxoby RJ, et al. COVID-19 vaccine attitudes and beliefs: a canadian national cross-sectional survey and cluster analysis. JMIR Public Health Surveill. 2021. https://doi.org/10.2196/30424.
Article
PubMed
PubMed Central
Google Scholar
Kochhar S, Dube E, Graham J, et al. COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER). Vaccine. 2021;39(18):2504–5.
Article
CAS
Google Scholar
Rele S. COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies. Hum Vaccin Immunother. 2021;17(4):1122–7.
Article
CAS
Google Scholar
Rodriguez-Martino E, Medina-Prieto R, Santana-Bagur J, et al. Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators. MedRxiv. 2021. https://doi.org/10.1101/2021.09.11.21263211.
Article
PubMed
PubMed Central
Google Scholar
Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, et al. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 2021;428:117607.
Article
CAS
Google Scholar
Singh J, Malik D, Raina A. Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus. Vaccine. 2021;39(7):1087–95.
Article
CAS
Google Scholar
Kim DS, Rowland-Jones S, Gea-Mallorqui E. Will SARS-CoV-2 infection elicit long-lasting protective or sterilising immunity? Implications for Vaccine Strategies (2020). Front Immunol. 2020;11:571481.
Article
CAS
Google Scholar
Karthik K, Senthilkumar TMA, Udhayavel S, et al. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother. 2020;16(12):3055–60.
Article
CAS
Google Scholar
Ulrich H, Pillat MM, Tarnok A. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective. Cytometry A. 2020;97(7):662–7.
Article
CAS
Google Scholar
Halstead SB, Katzelnick L. COVID-19 vaccines: should we fear ADE? J Infect Dis. 2020;222(12):1946–50.
Article
CAS
Google Scholar
Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72–3.
Article
CAS
Google Scholar
Bateman LB, Hall AG, Anderson WA, et al. Exploring COVID-19 vaccine hesitancy among stakeholders in African American and Latinx communities in the deep south through the lens of the health belief model. Am J Health Promot. 2021. https://doi.org/10.1177/08901171211045038.
Article
PubMed
PubMed Central
Google Scholar
Bendau A, Plag J, Petzold MB, et al. COVID-19 vaccine hesitancy and related fears and anxiety. Int Immunopharmacol. 2021;97:107724.
Article
CAS
Google Scholar
Bhagianadh D, Arora K. COVID-19 vaccine hesitancy among community-dwelling older adults: the role of information sources. J Appl Gerontol. 2021. https://doi.org/10.1177/07334648211037507.
Article
PubMed
Google Scholar
Blanchi S, Torreggiani M, Chatrenet A, et al. COVID-19 vaccine hesitancy in patients on dialysis in Italy and France. Kidney Int Rep. 2021;6(11):2763–74.
Article
Google Scholar
Pulliam JRC, Van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022. https://doi.org/10.1126/science.abn4947.
Article
PubMed
PubMed Central
Google Scholar
Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature. 2022. https://doi.org/10.1038/s41586-022-04865-0.
Article
PubMed
PubMed Central
Google Scholar
Victor PJ, Mathews KP, Paul H, et al. Protective effect of COVID-19 vaccine among health care workers during the second wave of the pandemic in India. Mayo Clin Proc. 2021;96(9):2493–4.
Article
CAS
Google Scholar
Mysore V, Cullere X, Settles ML, et al. Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. Med (N Y). 2021;2(9):1050-1071.e7.
CAS
Google Scholar
Gordon J, Reynolds M, Barnby E. An informative discussion for school nurses on COVID-19 mRNA vaccine. NASN Sch Nurse. 2021;36(3):132–6.
Article
Google Scholar